Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Rituximab in Relapsed CLL
NCT01539512Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Started Apr 2012; status: completed.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01539512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01539512.